Sign Out
Enablex should be administered with caution to patients with autonomic neuropathy, hiatus hernia, clinically significant bladder outflow obstruction, risk of urinary retention, severe constipation (defined as two or less bowel movements per week) or gastrointestinal obstructive disorders, such as pyloric stenosis.
Enablex should be used with caution in patients being treated for narrow-angle glaucoma (see CONTRAINDICATIONS).
Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Enablex. If urinary tract infection is present, an appropriate antibacterial therapy should be started.
Enablex should be used with caution in patients with risk of decreased gastrointestinal motility, gastroesophageal reflux and/or who are concurrently taking medicinal products (such as oral bisphosphonates) that can cause or exacerbate esophagitis.
Safety and efficacy have not yet been established in patients with a neurogenic cause for detrusor overactivity.
Caution should be used when prescribing antimuscarinics to patients with pre-existing cardiac diseases.
As with other antimuscarinics, patients should be instructed to discontinue Enablex and seek immediate medical attention if they experience edema of the tongue or laropharynx, or difficulty breathing (see ADVERSE REACTIONS).
Driving and using machines: No studies of the effects of Enablex on the ability to drive and use machines have been performed. However, Enablex may produce dizziness or blurred vision. Patients should not drive vehicles, use machines or perform other tasks which require alertness if they experience these adverse events.
